To ensure the quality and safety of medical services in primary healthcare institutions, China’s National Health Commission (NHC) and other relevant authorities issued a notice on 1 April 2026, outlining a three-year nationwide action.

Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

A new blood test is being developed to improve ovarian cancer diagnosis, with the potential to reduce unnecessary surgery leading to better health outcomes, saving time, stress and money for patients as well as the healthcare system.

To accelerate access to diagnostics in the continent, Africa CDC in partnership with key partners have launched the Africa Collaborative Initiative to Advance Diagnostics (AFCAD).

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

South Korean next-generation sequencing-based diagnostic firm NGeneBio said on Friday that it has entered a collaboration agreement with Chinese sequencing platform company MGI Tech to expand the commercial access of NGeneBio's cancer testing products.

Digital pathology firm Paige said Thursday it has forged a partnership with Ohio State University's Wexner Medical Center for a study to evaluate the use of artificial intelligence-assisted tools to diagnose prostate cancer in a community hospital setting.

Laboratory services company Labcorp has accelerated a strategy to drive growth through a string of healthcare system acquisitions and partnerships as its COVID PCR testing volumes have tapered off.

Wren Laboratories announced Thursday that it finalized a distribution agreement with Kindstar Globalgene Technology to distribute Wren's blood-based neuroendocrine tumor NETest throughout China.

GenInCode announced Wednesday that it filed a 510(k) submission for its CARDIO inCode-Score (CIC-Score) in vitro polygenic risk score (PRS) test for cardiovascular disease with the US Food and Drug Administration.

Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global science and technology innovator, today published its 2023 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year.